Droxicam

DB09215ApprovedWithdrawnSmall molecule

Droxicam is an oxicam non-steroidal anti-inflammatory drug and a prodrug of DB00554. It is used to reduce pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis.

Mechanism: Droxicam is converted to DB00554 via hydrolysis of the ester group in the intestine. Droxicam administration inhibits the synthesis of prostaglandins by cyclooxygenase enzymes.
Curator reviewed · 2 references
Primary indication: Droxicam is an NSAID previously used for the treatment of inflammation and rheumatoid arthritis.Curator reviewed
Formula / weight: C₁₆H₁₁N₃O₅S · 357.34 g/mol (avg)

Resolves to

Compound

UNIIF24ADO1E2DCAS90101-16-9ChEMBLCHEMBL1213420ChEBI76133PubChem65679KEGGD07267

Clinical / RWD

RxNorm23687ATCM01AC04PharmGKBPA166049182

Structure

InChIKeyOEHFRZLKGRKFAS-UHFFFAOYSA-NSMILESCN1C2=C(OC(=O)N(C2=O)C2=CC=CC=N2)C2=CC=CC=C2S1(=O)=O

Targets

P23219PTGS1P35354PTGS2

What you can answer from here — as of March 06, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1,665Drug interactionsStructured to mechanism, not free text

1ATC codeIncluding every combination product, plus 18 drug categories

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Droxicam, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In